🇺🇸 Supersaturated Calcium Phosphate in United States

60 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 60

Most-reported reactions

1. Cytokine Release Syndrome — 34 reports (56.67%)
2. Infusion Related Reaction — 11 reports (18.33%)
3. Neurotoxicity — 8 reports (13.33%)
4. Blood Bilirubin Increased — 1 report (1.67%)
5. Clostridium Difficile Colitis — 1 report (1.67%)
6. Dermatitis — 1 report (1.67%)
7. Diarrhoea — 1 report (1.67%)
8. Diffuse Large B-Cell Lymphoma — 1 report (1.67%)
9. Escherichia Bacteraemia — 1 report (1.67%)
10. Febrile Neutropenia — 1 report (1.67%)

Source database →

Frequently asked questions

Is Supersaturated Calcium Phosphate approved in United States?

Supersaturated Calcium Phosphate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Supersaturated Calcium Phosphate in United States?

Riyadh Colleges of Dentistry and Pharmacy is the originator. The local marketing authorisation holder may differ — check the official source linked above.